HIV associated lymphoma: latest updates from 2023 ASH annual meeting

Chaoyu Wang; Qing Xiao; Xiaomei Zhang; Yao Liu

doi:10.1186/s40164-024-00530-6

Experimental Hematology & Oncology (Jul 2024)

HIV associated lymphoma: latest updates from 2023 ASH annual meeting

Chaoyu Wang,
Qing Xiao,
Xiaomei Zhang,
Yao Liu

Affiliations

Chaoyu Wang: Department of Hematology, Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Chongqing University Cancer Hospital
Qing Xiao: Department of Hematology, Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Chongqing University Cancer Hospital
Xiaomei Zhang: Department of Hematology, Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Chongqing University Cancer Hospital
Yao Liu: Department of Hematology, Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Chongqing University Cancer Hospital

DOI: https://doi.org/10.1186/s40164-024-00530-6
Journal volume & issue: Vol. 13, no. 1
pp. 1 – 3

Abstract

Read online

Abstract The incidence, clinical characteristics, and prognostic factors of HIV-associated lymphoma remain poorly defined compared to HIV-negative lymphoma. Currently, there are no standard guidelines for treatment of these patients. We summarized several latest reports of HIV associated lymphoma from the 2023 ASH Annual Meeting (ASH2023).

Published in Experimental Hematology & Oncology

ISSN: 2162-3619 (Online)
Publisher: BMC
Country of publisher: United Kingdom
LCC subjects: Medicine: Internal medicine: Specialties of internal medicine: Diseases of the blood and blood-forming organs; Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://ehoonline.biomedcentral.com

About the journal